Tango Therapeutics reports 82% response rate in pancreatic cancer trial, plans Phase 3 study in 2027

Tango Therapeutics announced promising Phase 1/2 trial results for vopimetostat combined with daraxonrasib in treating MTAP-deleted, RAS-mutant pancreatic cancer, showing an 82% objective response rate and a 9-month progression-free survival rate of 88%. The combination was generally well-tolerated, with no dose-limiting toxicities at the primary dose level. Following positive FDA discussions, Tango plans to start a Phase 3 registrational trial in the first half of 2027 to compare this combination against standard chemotherapy in front-line patients. This development could mark a significant advance in treating a cancer type that is typically hard to manage and may expand to other tumor types in the future.

Tango Therapeutics Inc. (TNGX) shares are trading at USD 29.86, up 6.91% as of Oct 23, 2026 17:41 WIB on Pluang, reflecting strong investor interest following the promising Phase 1/2 trial results for their pancreatic cancer treatment. The stock's market cap stands at $4.71 billion with a 52-week high of $32.90, indicating robust market confidence. All Pluang orders are currently buys, highlighting positive sentiment around Tango's development strategy updates.